Hangzhou Alltest Biotech Co. Ltd. A (SHG:688606) — Market Cap & Net Worth
Market Cap & Net Worth: Hangzhou Alltest Biotech Co. Ltd. A (688606)
Hangzhou Alltest Biotech Co. Ltd. A (SHG:688606) has a market capitalization of $509.99 Million (CN¥3.49 Billion) as of July 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #12187 globally and #3525 in its home market, demonstrating a 7.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou Alltest Biotech Co. Ltd. A's stock price CN¥43.96 by its total outstanding shares 79280855 (79.28 Million). See 688606 capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Hangzhou Alltest Biotech Co. Ltd. A Market Cap History: 2021 to 2026
Hangzhou Alltest Biotech Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $761.09 Million to $496.65 Million (-12.96% CAGR).
Hangzhou Alltest Biotech Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou Alltest Biotech Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.81x
Hangzhou Alltest Biotech Co. Ltd. A's market cap is 0.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.40x
Hangzhou Alltest Biotech Co. Ltd. A's market cap is 3.40 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $761.09 Million | $1.87 Billion | $765.69 Million | 0.41x | 0.99x |
| 2022 | $665.57 Million | $3.39 Billion | $1.18 Billion | 0.20x | 0.56x |
| 2023 | $755.44 Million | $754.70 Million | $180.58 Million | 1.00x | 4.18x |
| 2024 | $734.36 Million | $866.58 Million | $302.47 Million | 0.85x | 2.43x |
| 2025 | $741.21 Million | $911.30 Million | $218.28 Million | 0.81x | 3.40x |
Competitor Companies of 688606 by Market Capitalization
Companies near Hangzhou Alltest Biotech Co. Ltd. A in the global market cap rankings as of July 8, 2026.
Key companies related to Hangzhou Alltest Biotech Co. Ltd. A by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #156 globally with a market cap of $148.77 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #270 globally with a market cap of $93.44 Billion USD ( €79.92 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #339 globally with a market cap of $78.07 Billion USD ( €66.78 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #537 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #156 | Intuitive Surgical Inc | NASDAQ:ISRG | $148.77 Billion | $432.83 |
| #270 | EssilorLuxottica S. A. | PA:EL | $93.44 Billion | €172.60 |
| #339 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $78.07 Billion | €85.00 |
| #537 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Hangzhou Alltest Biotech Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Hangzhou Alltest Biotech Co. Ltd. A's market cap moved from $761.09 Million to $ 496.65 Million, with a yearly change of -12.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥496.65 Million | -32.99% |
| 2025 | CN¥741.21 Million | +0.93% |
| 2024 | CN¥734.36 Million | -2.79% |
| 2023 | CN¥755.44 Million | +13.50% |
| 2022 | CN¥665.57 Million | -12.55% |
| 2021 | CN¥761.09 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 7th, 2026 the market cap of Hangzhou Alltest Biotech Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $509.99 Million USD |
| MoneyControl | $509.99 Million USD |
| MarketWatch | $509.99 Million USD |
| marketcap.company | $509.99 Million USD |
| Reuters | $509.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more